Price (delayed)
$16.26
Market cap
$3.79B
P/E Ratio
108.4
Dividend/share
N/A
EPS
$0.15
Enterprise value
$3.83B
ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at
There are no recent dividends present for ADMA.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from and Sharadar.